1'-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication.
Cheung, Peter Pak-Hang
KAUST DepartmentComputer Science Program
Computational Bioscience Research Center (CBRC)
Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division
Embargo End Date2022-03-10
Permanent link to this recordhttp://hdl.handle.net/10754/662846
MetadataShow full item record
AbstractCOVID-19 has recently caused a global health crisis and an effective interventional therapy is urgently needed. Remdesivir is one effective inhibitor for SARS-CoV-2 viral RNA replication. It supersedes other NTP analogues because it not only terminates the polymerization activity of RNA-dependent RNA polymerase (RdRp), but also inhibits the proofreading activity of intrinsic exoribonuclease (ExoN). Even though the static structure of Remdesivir binding to RdRp has been solved and biochemical experiments have suggested it to be a "delayed chain terminator", the underlying molecular mechanisms is not fully understood. Here, we performed all-atom molecular dynamics (MD) simulations with an accumulated simulation time of 24 microseconds to elucidate the inhibitory mechanism of Remdesivir on nucleotide addition and proofreading. We found that when Remdesivir locates at an upstream site in RdRp, the 1'-cyano group experiences electrostatic interactions with a salt bridge (Asp865-Lys593), which subsequently halts translocation. Our findings can supplement the current understanding of the delayed chain termination exerted by Remdesivir and provide an alternative molecular explanation about Remdesivir's inhibitory mechanism. Such inhibition also reduces the likelihood of Remdesivir to be cleaved by ExoN acting on 3'-terminal nucleotides. Furthermore, our study also suggests that Remdesivir's 1'-cyano group can disrupt the cleavage site of ExoN via steric interactions, leading to a further reduction in the cleavage efficiency. Our work provides plausible and novel mechanisms at the molecular level of how Remdesivir inhibits viral RNA replication, and our findings may guide rational design for new treatments of COVID-19 targeting viral replication.
CitationZhang, L., Zhang, D., Wang, X., Yuan, C., Li, Y., Jia, X., … Huang, X. (2021). 1′-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication. Physical Chemistry Chemical Physics. doi:10.1039/d0cp05948j
SponsorsThe authors acknowledge the National Natural Science Foundation of China Grants [grant number 21733007 and 21803071 to L. Z.], the Shenzhen Science and Technology Innovation Committee [grant number JCYJ20170413173837121 to X. H.], the Hong Kong Research Grant Council [grant number 16307718, 16318816, AoE/P-705/16, and T13-605/18-W to X. H.; 16301319 to P. P. C.], the Innovation and Technology Commission [grant number ITCPD/17-9 to X. H.] and the King Abdullah University of Science and Technology (KAUST) Office of Sponsored Research (OSR) [Award No. FCC/1/1976-18, FCC/1/1976-23, FCC/1/1976-26, URF/1/4098-01-01, REI/1/4473-01-01, and REI/1/0018-01-01 to X. G.]. This research made use of the computing resources of the Supercomputing Laboratory at King Abdullah University of Science and Technology.
PublisherRoyal Society of Chemistry (RSC)
- Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
- Authors: Zhang L, Zhou R
- Issue date: 2020 Aug 13
- Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
- Authors: Kokic G, Hillen HS, Tegunov D, Dienemann C, Seitz F, Schmitzova J, Farnung L, Siewert A, Höbartner C, Cramer P
- Issue date: 2021 Jan 12
- Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.
- Authors: Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M, Chang S, Xie YC, Tian G, Jiang HW, Tao SC, Shen J, Jiang Y, Jiang H, Xu Y, Zhang S, Zhang Y, Xu HE
- Issue date: 2020 Jun 26
- Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
- Authors: Shannon A, Le NT, Selisko B, Eydoux C, Alvarez K, Guillemot JC, Decroly E, Peersen O, Ferron F, Canard B
- Issue date: 2020 Jun
- Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication.
- Authors: Bravo JPK, Dangerfield TL, Taylor DW, Johnson KA
- Issue date: 2021 Apr 1